Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
READY-AD: JNJ-95597528 in Moderate to Severe Atopic Dermatitis
jRCT2031250657Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of JNJ-95597528 in atopic dermatitis (AD) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: EASI-75 response at Week 12. Started Jan 2026; status: active, not recruiting.
02
Drugs
JNJ-95597528
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250657.